Gilead Sciences, Inc. GILD
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $29.4B | +2% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Operating income | $10.0B | +503% | FY ending Dec 31, 2025 |
| Net income | $8.5B | +1673% | FY ending Dec 31, 2025 |
| Earnings per share | $6.78 | +1684% | FY ending Dec 31, 2025 |
| Research & development | $5.8B | -2% | FY ending Dec 31, 2025 |
| Cash from operations | $10.0B | -7% | FY ending Dec 31, 2025 |
| Capital spending | $563.0M | +8% | FY ending Dec 31, 2025 |
| Share buybacks | $1.9B | +67% | FY ending Dec 31, 2025 |
| Dividends paid | $4.0B | +2% | FY ending Dec 31, 2025 |
| Cash | $7.6B | -24% | FY ending Dec 31, 2025 |
| Long-term debt | $22.1B | -11% | FY ending Dec 31, 2025 |
| Shareholders' equity | $22.7B | +17% | FY ending Dec 31, 2025 |
| Shares outstanding | 1.24B | -0% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 0 open-market buys ($0) and 45 sales ($87.9M) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Andrew D DickinsonChief Financial Officer | Soldpre-set plan | 3,000 | $156.22 | $469K | Oct 15, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Soldpre-set plan | 3,000 | $156.22 | $469K | Oct 15, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan2 fills | 15,000 | $147.90 avg | $2.2M | Oct 1, 2026 |
| Andrew D DickinsonChief Financial Officer | Soldpre-set plan | 3,000 | $145.29 | $436K | Sep 15, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Soldpre-set plan3 fills | 3,000 | $144.22 avg | $433K | Sep 15, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan3 fills | 15,000 | $148.64 avg | $2.2M | Sep 1, 2026 |
| Anthony WeltersDirector | Soldpre-set plan4 fills | 18,000 | $148.62 avg | $2.7M | Aug 26, 2026 |
| Jeffrey BluestoneDirector | Soldpre-set plan5 fills | 5,000 | $145.02 avg | $725K | Aug 20, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Soldpre-set plan2 fills | 28,000 | $137.64 avg | $3.9M | Aug 17, 2026 |
| Andrew D DickinsonChief Financial Officer | Soldpre-set plan | 3,000 | $138.36 | $415K | Aug 17, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan3 fills | 15,000 | $130.31 avg | $2.0M | Aug 3, 2026 |
| Andrew D DickinsonChief Financial Officer | Soldpre-set plan | 3,000 | $129.93 | $390K | Jul 15, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Soldpre-set plan | 3,000 | $129.92 | $390K | Jul 15, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan2 fills | 15,000 | $126.29 avg | $1.9M | Jul 1, 2026 |
| Andrew D DickinsonChief Financial Officer | Soldpre-set plan | 3,000 | $125.40 | $376K | Jun 15, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Soldpre-set plan3 fills | 3,000 | $123.92 avg | $372K | Jun 15, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan3 fills | 15,000 | $131.46 avg | $2.0M | Jun 1, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Soldpre-set plan4 fills | 28,000 | $131.29 avg | $3.7M | May 15, 2026 |
| Andrew D DickinsonChief Financial Officer | Soldpre-set plan | 3,000 | $132.27 | $397K | May 15, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan2 fills | 10,000 | $129.16 avg | $1.3M | Apr 28, 2026 |
| Andrew D DickinsonChief Financial Officer | Soldpre-set plan | 3,000 | $140.96 | $423K | Apr 15, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Soldpre-set plan | 3,000 | $140.96 | $423K | Apr 15, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan | 10,000 | $136.82 | $1.4M | Mar 27, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Soldpre-set plan | 3,000 | $144.23 | $433K | Mar 16, 2026 |
| Andrew D DickinsonChief Financial Officer | Soldpre-set plan | 3,000 | $144.23 | $433K | Mar 16, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan3 fills | 10,000 | $144.79 avg | $1.4M | Feb 27, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Soldpre-set plan3 fills | 28,000 | $154.44 avg | $4.3M | Feb 17, 2026 |
| Andrew D DickinsonChief Financial Officer | Soldpre-set plan | 3,000 | $154.43 | $463K | Feb 17, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan | 115,640 | $150.00 | $17.3M | Feb 5, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan2 fills | 10,000 | $139.89 avg | $1.4M | Jan 28, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan | 115,640 | $135.00 | $15.6M | Jan 23, 2026 |
| Jeffrey BluestoneDirector | Soldpre-set plan | 5,000 | $123.50 | $618K | Jan 20, 2026 |
| Andrew D DickinsonChief Financial Officer | Soldpre-set plan | 3,000 | $124.31 | $373K | Jan 15, 2026 |
| Johanna MercierChief Commercial Officer | Soldpre-set plan | 3,000 | $124.31 | $373K | Jan 15, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan | 10,000 | $124.83 | $1.2M | Dec 29, 2025 |
| Andrew D DickinsonChief Financial Officer | Soldpre-set plan | 3,000 | $122.00 | $366K | Dec 15, 2025 |
| Johanna MercierChief Commercial Officer | Soldpre-set plan | 3,000 | $122.00 | $366K | Dec 15, 2025 |
| Daniel Patrick O'DayChairman & CEO, Director | Soldpre-set plan2 fills | 10,000 | $126.54 avg | $1.3M | Nov 28, 2025 |
| Jeffrey BluestoneDirector | Sold | 5,000 | $125.08 | $625K | Nov 28, 2025 |
| Kelly A. KramerDirector | Soldpre-set plan | 2,805 | $127.10 | $357K | Nov 28, 2025 |
Other insider moves (75): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Erin BurkhartSVP, Controllership | Tax withholding | 768 | $152.67 | $117K | Sep 22, 2026 |
| Erin BurkhartSVP, Controllership | Option exercise | 2,223 | – | – | Sep 22, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Tax withholding | 4,230 | $144.81 | $613K | Sep 10, 2026 |
| Andrew D DickinsonChief Financial Officer | Tax withholding | 1,347 | $144.81 | $195K | Sep 10, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Tax withholding | 1,347 | $144.81 | $195K | Sep 10, 2026 |
| Wettan Keeley M CainEVP Gen Counsel, Legal & Comp | Tax withholding | 285 | $144.81 | $41K | Sep 10, 2026 |
| Dietmar BergerChief Medical Officer | Tax withholding | 263 | $144.81 | $38K | Sep 10, 2026 |
| Andrew D DickinsonChief Financial Officer | Option exercise | 2,797 | – | – | Sep 10, 2026 |
| Dietmar BergerChief Medical Officer | Option exercise | 533 | – | – | Sep 10, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Option exercise | 2,797 | – | – | Sep 10, 2026 |
| Wettan Keeley M CainEVP Gen Counsel, Legal & Comp | Option exercise | 590 | – | – | Sep 10, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Option exercise | 8,780 | – | – | Sep 10, 2026 |
| Anthony WeltersDirector | Option exercisepre-set plan2 fills | 18,000 | $61.06 avg | $1.1M | Aug 26, 2026 |
| Jeffrey BluestoneDirector | Option exercisepre-set plan5 fills | 5,000 | $67.04 avg | $335K | Aug 20, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Option exercisepre-set plan2 fills | 25,000 | $67.07 avg | $1.7M | Aug 17, 2026 |
| Wettan Keeley M CainEVP Gen Counsel, Legal & Comp | Tax withholding | 2,908 | $133.06 | $387K | Aug 10, 2026 |
| Wettan Keeley M CainEVP Gen Counsel, Legal & Comp | Option exercise | 6,002 | – | – | Aug 10, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Tax withholding | 4,213 | $121.48 | $512K | Jun 10, 2026 |
| Andrew D DickinsonChief Financial Officer | Tax withholding | 1,341 | $121.48 | $163K | Jun 10, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Tax withholding | 1,341 | $121.48 | $163K | Jun 10, 2026 |
| Wettan Keeley M CainEVP Gen Counsel, Legal & Comp | Tax withholding | 283 | $121.48 | $34K | Jun 10, 2026 |
| Dietmar BergerChief Medical Officer | Tax withholding | 263 | $121.48 | $32K | Jun 10, 2026 |
| Dietmar BergerChief Medical Officer | Option exercise | 533 | – | – | Jun 10, 2026 |
| Wettan Keeley M CainEVP Gen Counsel, Legal & Comp | Option exercise | 589 | – | – | Jun 10, 2026 |
| Andrew D DickinsonChief Financial Officer | Option exercise | 2,796 | – | – | Jun 10, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Option exercise | 2,796 | – | – | Jun 10, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Option exercise | 8,779 | – | – | Jun 10, 2026 |
| Gilead Sciences, Inc.10% owner | Award | 471,698 | $26.50 | $12.5M | May 26, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Option exercisepre-set plan | 25,000 | $66.64 | $1.7M | May 15, 2026 |
| Harish ManwaniDirector | Tax withholding | 224 | $130.84 | $29K | Apr 30, 2026 |
| Jeffrey BluestoneDirector | Award | 1,146 | – | – | Apr 30, 2026 |
| Jacqueline K BartonDirector | Award | 1,146 | – | – | Apr 30, 2026 |
| Sandra HorningDirector | Award | 1,146 | – | – | Apr 30, 2026 |
| Ted W LoveDirector | Award | 1,146 | – | – | Apr 30, 2026 |
| Javier RodriguezDirector | Award | 1,146 | – | – | Apr 30, 2026 |
| Anthony WeltersDirector | Award | 1,146 | – | – | Apr 30, 2026 |
| Harish ManwaniDirector | Award | 1,146 | – | – | Apr 30, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Tax withholding | 9,767 | $148.56 | $1.5M | Mar 10, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Tax withholding | 3,216 | $148.56 | $478K | Mar 10, 2026 |
| Andrew D DickinsonChief Financial Officer | Tax withholding | 3,147 | $148.56 | $468K | Mar 10, 2026 |
| Dietmar BergerChief Medical Officer | Tax withholding | 1,063 | $148.56 | $158K | Mar 10, 2026 |
| Wettan Keeley M CainEVP Gen Counsel, Legal & Comp | Tax withholding | 606 | $148.56 | $90K | Mar 10, 2026 |
| Andrew D DickinsonChief Financial Officer | Option exercise | 6,469 | – | – | Mar 10, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Option exercise | 6,617 | – | – | Mar 10, 2026 |
| Wettan Keeley M CainEVP Gen Counsel, Legal & Comp | Option exercise | 1,246 | – | – | Mar 10, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Option exercise | 20,026 | – | – | Mar 10, 2026 |
| Dietmar BergerChief Medical Officer | Option exercise | 2,133 | – | – | Mar 10, 2026 |
| Andrew D DickinsonChief Financial Officer | Award | 11,090 | – | – | Feb 27, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Award | 11,090 | – | – | Feb 27, 2026 |
| Dietmar BergerChief Medical Officer | Award | 8,530 | – | – | Feb 27, 2026 |
| Wettan Keeley M CainEVP Gen Counsel, Legal & Comp | Award | 470 | – | – | Feb 27, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Awardpre-set plan | 38,396 | – | – | Feb 27, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Option exercisepre-set plan | 25,000 | $66.64 | $1.7M | Feb 17, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Option exercisepre-set plan | 115,640 | $66.01 | $7.6M | Feb 5, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Tax withholding | 74,461 | $143.28 | $10.7M | Feb 3, 2026 |
| Andrew D DickinsonChief Financial Officer | Tax withholding | 24,802 | $143.28 | $3.6M | Feb 3, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Tax withholding | 24,800 | $143.28 | $3.6M | Feb 3, 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | Award | 44,867 | – | – | Feb 3, 2026 |
| Andrew D DickinsonChief Financial Officer | Award | 44,867 | – | – | Feb 3, 2026 |
| Daniel Patrick O'DayChairman & CEO, Director | Award | 131,675 | – | – | Feb 3, 2026 |
Trades by members of Congress
6 members reported 10 buys and 3 sales since Oct 29, 2024. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Jared Moskowitz D | Bought | $1,001–$15K | May 6, 2026 | Jun 19, 2026 | Child |
| Jared Moskowitz D | Bought | $1,001–$15K | May 6, 2026 | Jun 19, 2026 | Self |
| Josh Gottheimer D | Bought | $1,001–$15K | Jan 27, 2026 | Feb 26, 2026 | Joint |
| Val T. Hoyle D | Sold | $1,001–$15K | Sep 23, 2025 | Oct 10, 2025 | Spouse |
| Val T. Hoyle D | Bought | $1,001–$15K | Oct 29, 2024 | Sep 12, 2025318 days later | Spouse |
| Jefferson Shreve R | Sold | $15K–$50K | May 12, 2025 | Jun 22, 2025 | Self |
| Marjorie Taylor Greene R | Bought | $1,001–$15K | Jun 6, 2025 | Jun 18, 2025 | Self |
| Josh Gottheimer D | Sold | $1,001–$15K | May 14, 2025 | Jun 11, 2025 | Joint |
| Marjorie Taylor Greene R | Bought | $1,001–$15K | May 5, 2025 | May 6, 2025 | Self |
| Marjorie Taylor Greene R | Bought | $1,001–$15K | May 5, 2025 | May 6, 2025 | Self |
| Jefferson Shreve R | Bought | $15K–$50K | Mar 31, 2025 | Apr 11, 2025 | Self |
| Carol D. Miller R | Bought | $1,001–$15K | Mar 10, 2025 | Apr 11, 2025 | Self |
| Josh Gottheimer D | Bought | $1,001–$15K | Mar 7, 2025 | Apr 10, 2025 | Joint |
Latest SEC filings
- Insider plans to sell 144 · Oct 15, 2026
- Insider plans to sell 144 · Oct 15, 2026
- Insider plans to sell 144 · Sep 15, 2026
- Insider plans to sell 144 · Sep 15, 2026
- Insider plans to sell 144 · Aug 26, 2026
- Insider plans to sell 144 · Aug 20, 2026
- Insider plans to sell 144 · Aug 17, 2026
- Insider plans to sell 144 · Aug 17, 2026
- Quarterly report 10-Q · Aug 6, 2026
- News filing: Quarterly results 8-K · Aug 4, 2026
- Insider plans to sell 144 · Aug 3, 2026
- Insider plans to sell 144 · Jul 15, 2026
- Insider plans to sell 144 · Jul 15, 2026
- Insider plans to sell 144 · Jun 15, 2026
- Insider plans to sell 144 · Jun 15, 2026
- Insider plans to sell 144 · Jun 1, 2026
- News filing: Signed a major agreement, Took on new debt, Other news 8-K · May 20, 2026
- Insider plans to sell 144 · May 15, 2026
- Insider plans to sell 144 · May 15, 2026
- Quarterly report 10-Q · May 7, 2026
- News filing: Quarterly results 8-K · May 7, 2026
- News filing: Shareholder vote results 8-K · May 4, 2026
- Insider plans to sell 144 · Apr 28, 2026
- News filing: Public announcement (Reg FD), Other news 8-K · Apr 28, 2026
- Insider plans to sell 144 · Apr 15, 2026
About Gilead Sciences, Inc.
Business description
- Industry
- Biological Products, (No Diagnostic Substances)
- Sector
- Life Sciences
- Headquarters
- Foster City, CA
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Exchange
- Nasdaq
- Filer size
- Large accelerated filer
- Formerly
- GILEAD SCIENCES INC
- SEC company number (CIK)
- 882095
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.